Search clinical trials for: Identification of semaphorin gene polymorphisms

Total 819 results

Tel Aviv University
Zohar Landau; Shani Tsameret

Unknown

Influence of Dairy Protein Breakfast on Glycemia, Weight Loss and Clock Genes in T2D (Mdiet)

Type2 Diabetes | Healthy Obesity, Metabolically

Israel
XenoPort, Inc.

Completed

Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study (CONCORD)

Restless Legs Syndrome

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia and other conditions

United States
Stephen Harbarth
European Commission

Unknown

Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy (R-GNOSIS WP3)

Intestinal Colonization With Multidrug-resistant Bacteria

Israel, Switzerland, France, Netherlands
University of South Florida

Completed

Minocycline in the Treatment of Angelman Syndrome

Angelman Syndrome

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma

United States
Northwestern University
Seagen Inc.; Robert H. Lurie Cancer Center

Unknown

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
State University of New York at Buffalo

Completed

Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy (RA-TLH)

Pain, Postoperative

United States
Case Comprehensive Cancer Center

Completed

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma...

United States
Pamukkale University

Unknown

Comparison of Dexketoprofen, Paracetamol and Ibuprofen in the Treatment of Primary Dysmenorrhea

Dysmenorrhea

Turkey
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

Aplastic Anemia

United States
Allergan

Completed

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Ocular Hypertension | Glaucoma

United States
Pachankis, Yang I., M.D.
First Affiliated Hospital of Chongqing Medical University

Completed

Detoxification From the Lipid Tract

COVID-19 Vaccine Adverse Reaction

China
University of L'Aquila

Completed

Clinical and Histological Evaluation of Deproteinizated Bovine Bone Allograft and Lyophilized Equine Bone Allograft for Sinus Lift.

Maxillary Sinus Floor Augmentation
Bahria University

Completed

To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea

Irritable Bowel Syndrome With Diarrhea

Pakistan
Medical Research Council

Completed

Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer

Colorectal Cancer

United Kingdom
The University of New South Wales

Completed

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United Kingdom
Janssen Scientific Affairs, LLC

Completed

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) (FIRST)

Schizophrenia

United States
Wake Forest University Health Sciences

Recruiting

NextGen - Clinical Implication of Next Generation Sequencing

Urinary Tract Infections

United States
University Hospital, Ghent

Completed

Multimodal Versus Opioid aNalgesia in carDiAc Surgery (MONDAY)

Postoperative Pain | Postoperative Delirium

Belgium
XenoPort, Inc.

Completed

Simulated Driving Study in Restless Legs Syndrome (XP083)

Restless Legs Syndrome

United States
University of Colorado, Denver
University of Aarhus

Completed

Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

Nephrogenic Diabetes Insipidus

United States, Denmark
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Sezary Syndrome | Refractory T-Cell Non-Hodgkin Lymphoma | Merkel Cell Carcinoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extramammary Paget Disease | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Refractory Mature T-Cell and NK-Cell Non-Hodgkin... and other conditions

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

Follicular Lymphoma

United States
Academic and Community Cancer Research United

Not yet recruiting

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Primary Mediastinal Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Recurrent Non-Small Cell Lung Carcinoma | Recurrent Pleural Malignant Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage IV Pleural Malignant Mesothelioma AJCC v7 | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | HLA-A*0201 Positive... and other conditions

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Population Pharmacokinetics of Antiepileptic in Pediatrics (EPIPOP)

Epilepsy

France
Jonsson Comprehensive Cancer Center

Active, not recruiting

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Malignant Neoplasm

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast Carcinoma

United States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
National Cancer Institute (NCI)

Completed

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive | Male Breast Carcinoma

United States
National Cancer Institute (NCI)

Withdrawn

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
University of Nebraska
National Cancer Institute (NCI)

Completed

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Metastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...

United States
University of California, San Francisco
Amgen

Active, not recruiting

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult... and other conditions

United States, Germany
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
National Cancer Institute (NCI)

Not yet recruiting

Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Stage 0 Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | HER2/Neu Negative | Postmenopausal

United States
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)

Hormone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Australia, Puerto Rico, New Zealand, Ireland, Peru, United Kingdom
Northwestern University
National Cancer Institute (NCI); BHR Pharma, LLC

Recruiting

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Estrogen Receptor Positive | Ductal Breast Carcinoma In Situ

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Advanced Malignant Neoplasm | Dermatologic Complication

United States
Beijing Children's Hospital
Hopital Universitaire Robert-Debre; Shandong University; Rennes University Hospital

Recruiting

Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

Tuberculosis

China
Alexandria University

Completed

The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study

Bacterial Keratitis | Fungal Keratitis | Mixed Bacterial and Fungal Keratitis | Microbial Keratitis

Egypt
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland

Search clinical trials for: Identification of semaphorin gene polymorphisms

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations